Literature DB >> 11518421

Treatment of partial seizures and seizure-like activity with felbamate in six dogs.

D Ruehlmann1, M Podell, P March.   

Abstract

Six dogs with partial seizures or partial seizure-like activity were treated with the antiepileptic drug felbamate between 1993 and 1998. All dogs had a history and results of diagnostic testing suggestive of either primary (idiopathic) or occult secondary epilepsy. Dogs ranged between four months and eight years of age at the onset of seizure activity. The median time period between onset of the first seizure and the start of felbamate therapy was 3.8 months (range 0.75 to 36 months). Median duration of therapy was nine months (range two to 22 months). All dogs experienced a reduction in seizure frequency after felbamate administration. Median total number of seizures post-treatment was two (range 0 to 9). Two dogs had an immediate and prolonged cessation of seizure activity. Steady-state trough serum felbamate concentrations measured at two weeks, and one, 12 and 22 months after the commencement of therapy in four dogs ranged between 13 and 55 mg/litre (median 35 mg/litre). Reversible haematological adverse effects were detected in two dogs, with one dog developing concurrent keratoconjunctivitis sicca. These results suggest that felbamate can be an effective antiepileptic drug without life-threatening complications when used as monotherapy for partial seizures in the dog.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518421     DOI: 10.1111/j.1748-5827.2001.tb02490.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  6 in total

1.  International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe.

Authors:  Sofie F M Bhatti; Luisa De Risio; Karen Muñana; Jacques Penderis; Veronika M Stein; Andrea Tipold; Mette Berendt; Robyn G Farquhar; Andrea Fischer; Sam Long; Wolfgang Löscher; Paul J J Mandigers; Kaspar Matiasek; Akos Pakozdy; Edward E Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Clare Rusbridge; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

Review 2.  Treatment in canine epilepsy--a systematic review.

Authors:  Marios Charalambous; David Brodbelt; Holger A Volk
Journal:  BMC Vet Res       Date:  2014-10-22       Impact factor: 2.741

3.  Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy.

Authors:  Curtis Wells Dewey; Mark Rishniw; Kasie Sakovitch
Journal:  Open Vet J       Date:  2022-07-11

Review 4.  Antiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogs.

Authors:  Marios Charalambous; Sara K Shivapour; David C Brodbelt; Holger A Volk
Journal:  BMC Vet Res       Date:  2016-05-21       Impact factor: 2.741

Review 5.  Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management.

Authors:  Pier Luigi Dodi
Journal:  Vet Med (Auckl)       Date:  2015-10-30

Review 6.  Pediatric seizure disorders in dogs and cats.

Authors:  James A Lavely
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-12-05       Impact factor: 2.093

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.